Clinical Trial Update: Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating Cadonilimab (AK104) in combination with chemotherapy and Bevacizumab as first-line therapy for patients with RAS-mutated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Cadonilimab (AK104) (Cadonilimab)
• Chemotherapy (unspecified)

Snippet

Sponsor: Caigang Liu | Conditions: Colorectal Cancer | Phase 3 | Status: RECRUITING